September 29, 2022Open Access

Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy

Key Points

Key points are not available for this paper at this time.

Abstract

Our current findings do not support that HER2-low BC had different biology and clinical features compared to HER2-zero BC in patients who treated with neoadjuvant chemotherapy. However, the prognostic impact of HER2-low status in BC remains controversial; thus warranting further research.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Kang et al. (Thu,) studied this question.

synapsesocial.com/papers/69d9692e00ab073a27836719 https://doi.org/https://doi.org/10.1016/j.ejca.2022.08.031

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study2019 · 566 citations
2The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis2021 · 59 citations
3The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy2019 · 431 citations
4Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer2013 · 97 citations
5Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update2018 · 2,457 citations

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper